Paolo Tarantino/X
Jul 12, 2025, 23:29
Paolo Tarantino: CDK4/6 inhibitor rechallenge/switch – should we?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“CDK4/6 inhibitor rechallenge/switch: should we? Positive data from postMONARCH, though with only a small (<1 mo) PFS advantage, and EMBER-3 suggesting a greater PFS advantage with imlunestrant/abema (not yet approved). Controversy remains.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 13, 2025, 00:47
Jul 12, 2025, 23:29
Jul 12, 2025, 23:19
Jul 12, 2025, 20:03
Jul 12, 2025, 18:58